{Reference Type}: Journal Article
{Title}: Sacituzumab Govitecan Demonstrates Efficacy across Tumor Trop-2 Expression Levels in Patients with Advanced Urothelial Cancer.
{Author}: Loriot Y;Balar AV;Petrylak DP;Kalebasty AR;Grivas P;Fléchon A;Jain RK;Swami U;Bupathi M;Barthélémy P;Beuzeboc P;Palmbos P;Kyriakopoulos CE;Pouessel D;Sternberg CN;Tonelli J;Sierecki M;Zavodovskaya M;Elboudwarej E;Diehl L;Jürgensmeier JM;Tagawa ST;
{Journal}: Clin Cancer Res
{Volume}: 30
{Issue}: 15
{Year}: 2024 Aug 1
{Factor}: 13.801
{DOI}: 10.1158/1078-0432.CCR-23-3924
{Abstract}: <B>UNASSIGNED: </B>Human trophoblast cell surface antigen 2 (Trop-2) is a protein highly expressed in urothelial cancer (UC). Sacituzumab govitecan (SG) is a Trop-2-directed antibody drug conjugate with a hydrolysable linker and a potent SN-38 payload. This study explored Trop-2 expression in tumors treated with SG in cohorts 1 to 3 (C1-3) from the TROPHY-U-01 study and evaluated whether efficacy was associated with Trop-2 expression.<BR><B>UNASSIGNED: </B>TROPHY-U-01 (NCT03547973) is an open-label phase II study that assessed the efficacy and safety of SG (alone or in combinations) in patients with unresectable locally advanced or metastatic UC (mUC). Archival tumor samples collected at enrollment for C1-3 were analyzed for Trop-2 membrane expression by considering histological scores (H-scores; scale 0-300) and the percentage of membrane positive tumor cells at low magnification (4×). The association of Trop-2 with clinical endpoints [objective response rate (ORR), progression-free survival (PFS), and overall survival (OS)] was evaluated.<BR><B>UNASSIGNED: </B>In C1-3, tissue was collected from 158 (82%) of 192 treated patients, and 146 (76%) had evaluable Trop-2 data. Trop-2 was highly expressed in tumor samples. The median [interquartile range (IQR)] Trop-2 H-score was 215 (180-246), and the median (IQR) percentage of membrane positive tumor cells was 91% (80-98). Trop-2 expression at any level was observed in 98% of patients. Furthermore, ORR, PFS, and OS benefits were observed across all Trop-2 expression levels.<BR><B>UNASSIGNED: </B>Trop-2 protein is highly expressed in UC, as confirmed by examining tumors from patients enrolled in the TROPHY-U-01 trial. The results indicate that SG demonstrates efficacy in mUC across Trop-2 expression levels.